Education
About Us
Working with TipRanks
Follow Us
Ceribell, Inc. (CBLL)
NASDAQ:CBLL
CBLL Stock Chart & Stats
$23.07
-$0.15(-0.64%)
At close: 4:00 PM EST
$23.07
-$0.15(-0.64%)
Day’s Range― - ―
52-Week Range$10.01 - $26.04
Previous CloseN/A
Volume46.56K
Average Volume (3M)519.80K
Market Cap
$869.15M
Enterprise Value$275.71M
Total Cash (Recent Filing)$168.54M
Total Debt (Recent Filing)$21.34M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 03, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding37,095,690
10 Day Avg. Volume488,814
30 Day Avg. Volume519,798
Financial Highlights & Ratios
PEG Ratio1.93
Price to Book (P/B)4.22
Price to Sales (P/S)12.34
P/FCF Ratio-22.20
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue3.33
Enterprise Value/Gross Profit3.78
Enterprise Value/Ebitda-5.61
Forecast
1Y Price Target
$25.17Price Target Upside9.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.46
Revenue Forecast (FY)$112.67M
Bulls Say, Bears Say
Bulls Say
Commercial TractionRevenue that exceeded expectations, increasing adoption by new accounts and deeper usage in existing accounts, along with management raising revenue guidance, signals sustained sales momentum and improving commercial execution.
Market Expansion And ReimbursementNeonatal and pediatric clearances plus a submitted New Technology Add-on Payment application and an expanded addressable market support meaningful TAM growth and the potential for improved reimbursement-driven adoption.
Regulatory MilestonesFDA clearances and breakthrough device designations across stroke, delirium and neonatal seizure detection position the company as a potential first-in-class point-of-care EEG provider, strengthening clinical credibility and market differentiation.
Bears Say
Legal RiskOngoing patent litigation creates uncertainty that could delay regulatory outcomes, complicate commercialization plans and act as a legal overhang on the stock.
Product Rollout UncertaintyUnclear timing for the delirium indication rollout leaves the magnitude and timing of revenue and adoption from that indication uncertain until company provides more detailed guidance.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.01 and its highest was $26.04 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $869.15M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is Mar 03, 2026 which is in 48 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on Nov 04, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.044.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.41.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 37,095,690 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 7.875%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.17 (9.10% Upside)
$25.17 (9.10% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.35%
12-Months-Change
Fundamentals
Return on Equity
-59.78%
Trailing 12-Months
Asset Growth
323.99%
Trailing 12-Months
Company Description
Ceribell, Inc.
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
CBLL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Ceribell demonstrated strong revenue growth and notable expansion in accounts, particularly within the VA system. However, increased operating expenses and net loss were significant concerns. The company is actively managing tariff impacts with supply chain adjustments.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$25.17
▲(9.10% Upside)
Technical Analysis
Ownership Overview
16.65% Insiders
21.44% Mutual Funds
32.08% Other Institutional Investors
22.95% Public Companies and
Individual Investors